Predictive and personalized medicine of pancreatic cancer
French National Research Agency (ANR)  
Funder: French National Research Agency (ANR)Project code: ANR-21-CE17-0024
Funder Contribution: 747,465 EUR
The CancerProfile multidisciplinary project brings together highly complementary translational research institutes to develop a novel standard of patient stratification for predictive and personalized medicine of pancreatic adenocarcinoma cancer. The overall objective is to fully integrate cutting-edge AI-augmented anatomopathology, genomics, and tissue/liquid biopsy analysis in conjunction with functional drug response of tumors, to derive biomarkers indicative of a predictive treatment choice. We will apply an innovative Personalized Functional Profiling (PFP) proprietary technology consisting of direct large-scale analysis of the sensitivity of 3D-printed spheroids derived from patient biopsies in response to a panel of EMA and FDA approved anti-cancer chemotherapeutics. Overall, the objective is to clinically validate new prognostic markers and identify alternative treatment options for tumors resistant to standard chemotherapies.
Data Management Plans